首页> 外文期刊>The FEBS journal >The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria
【24h】

The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria

机译:恶性疟原虫20S蛋白酶体的低温EM结构及其在抗击疟疾中的用途

获取原文
获取原文并翻译 | 示例
           

摘要

Plasmodium falciparum is the parasite responsible for the most severe form of malaria. Its increasing resistance to existing antimalarials represents a major threat to human health and urges the development of new therapeutic strategies to fight malaria. The proteasome is a protease complex essential in all eukaryotes. Accordingly, inhibition of the Plasmodium 20S proteasome is highly toxic for the parasite at all of its infective and developmental stages. Proteasome inhibitors have antimalarial potential both as curative and transmission blocking agents, but in order to have therapeutic application, they must specifically target the Plasmodium proteasome and not its human counterpart. X-ray crystallography has been widely used to determine structures of yeast and mammalian 20S proteasomes with ligands. However, crystallisation of the Plasmodium proteasome is challenging, as only small quantities of the complex can be directly purified from the parasite. Furthermore, most X-ray structures of proteasome-inhibitor complexes require soaking of crystals with high concentrations of ligand, thus preventing analysis of inhibitor subunit specificity. Instead we chose to determine the Plasmodium falciparum 20S proteasome structure, in the presence of a newrationally designed parasite-specific inhibitor, by high-resolution electron cryo-microscopy and single particle analysis. The resulting map, at a resolution of about 3.6 A, allows a direct molecular analysis of inhibitor/enzyme interactions. Here we present an overview of this structure, and how it provides valuable information that can be used to assist in the design of improved proteasome inhibitors with the potential to be developed as next-generation antimalarial drugs.
机译:恶性疟原虫是导致最严重形式的疟疾的寄生虫。它对现有抗疟药的抗药性日益增强,这对人类健康构成了重大威胁,并敦促开发新的抗疟疾治疗策略。蛋白酶体是所有真核生物必不可少的蛋白酶复合物。因此,在所有感染和发育阶段,对疟原虫20S蛋白酶体的抑制对于该寄生虫都是剧毒的。蛋白酶体抑制剂具有治愈和传播阻断剂的抗疟疾潜力,但是为了具有治疗应用,它们必须特异性地靶向疟原虫蛋白酶体而不是其人类对应物。 X射线晶体学已被广泛用于确定具有配体的酵母和哺乳动物20S蛋白酶体的结构。然而,疟原虫蛋白酶体的结晶是具有挑战性的,因为只能从寄生虫中直接纯化出少量的复合物。此外,蛋白酶体-抑制剂复合物的大多数X射线结构都需要浸泡具有高浓度配体的晶体,从而阻止了对抑制剂亚基特异性的分析。相反,我们选择通过高分辨率电子冷冻显微镜和单颗粒分析在新设计的寄生虫特异性抑制剂存在下确定恶性疟原虫20S蛋白酶体的结构。所得图谱的分辨率约为3.6 A,可直接进行抑制剂/酶相互作用的分子分析。在这里,我们概述了这种结构,以及它如何提供有价值的信息,可用于协助设计改进的蛋白酶体抑制剂,并有可能被开发为下一代抗疟药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号